Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) closing bell: the overbought are getting riper

June 18, 2018 5:44pm

Even as the session reduced losses with low volume to the upside and higher volume to the downside

Gene editing stocks - CRSP (+$3.32), EDIT (+$1.73) and NTLA (+$1.56) are headed into SELL zone

Out and about: Stories of the day – SLDB jumps, BSTG is up on what (?) and VSTM is up and stutters as ATHX gets no respect

Of the 45 covered the 22 downside equities finished in a range of -$0.01 to -$2.15 with biggest bottoms of -$6.45 and $3.70 and $2.97 while the 20 upside equities oscillated from +$0.01 to $2.88 with a topper of $3.32 and 3 flat closes

We keep you informed, if you want to make a return on investment (ROI) from the sector - be a subscriber!

There is no breadline for fact based intelligence!

Members only. Please login.

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

34 min ago
RegMed Investors’ (RMi) pre-open: finding our way

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.